Baixar PDF
Artigo anterior
Voltar à página
Artigo seguinte
If you have problems to see the content please click here
Outros usuários também visualizaram estes artigos
PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RR Barreto; K Patel; C Coombs; N Shah; T Eyre; W Wierda; P Ghia; M Davids; W Jurczak; A Mato;
Hematol Transfus Cell Ther. 2022;44 Supl 2:S139-40
PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP
NN Shah; PL Zinzani; TA Eyre; K Izutsu; AJ Alencar; K Patel; T Munir; DE Tsai; ML Wang; LYGN Presenter;
Hematol Transfus Cell Ther. 2023;45 Supl 4:S359-60
PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RRBN Presenter; N Shah; A Alencar; J Gerson; M Patel; W Jurczak; K Patel; A Mato; C Cheah; M Wang;
Hematol Transfus Cell Ther. 2022;44 Supl 2:S127